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Aims Growing evidence suggests that arginase misregulation plays a key role in the pathophysiology of essential hyperten-
sion. In the present study, we investigated the potential cardiovascular therapeutic effects of a long-term treatment
with an arginase inhibitor in adult spontaneously hypertensive rats (SHR) with fully developed hypertension.
Methods
and results
Treatment of 25-week-old SHR with the arginase inhibitor Nv-hydroxy-nor-L-arginine (nor-NOHA, 40 mg/day for
10 weeks) sustainably reduced systolic blood pressure (230 mmHg, P, 0.05). The antihypertensive effect of
nor-NOHA was associated with changes on mesenteric artery reactivity including the restoration of angiotensin-
II-induced contraction and acetylcholine-induced vasodilation to the values of normotensive Wistar Kyoto rats.
Both nitric oxide synthase and cyclooxygenase-dependent mechanisms account for the improvement of endothelial
function afforded by the arginase inhibitor, which in addition blunted hypertension-induced endothelial arginase I
overexpression in mesenteric arteries. Nor-NOHA also prevented the remodelling of aorta as measured by collagen
content and media/lumen ratio, and improved the compliance of carotid artery in SHR. Cardiac fibrosis assessed by
collagen content of left heart ventricle was reduced by nor-NOHA, with no significant effect on cardiac hypertrophy.
Conclusion Our results report that a long-term treatment with an arginase inhibitor reduced blood pressure, improved vascular
function, and reduced cardiac fibrosis in SHR with fully developed hypertension. These data suggest that arginase
represents a promising novel target for pharmacological intervention in essential hypertension.
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1. Introduction
Arginase (EC 3.5.3.1) is a hydrolytic enzyme responsible for convert-
ing L-arginine to urea and L-ornithine, the synthesis precursor of poly-
amines. Mammalian arginases exist in two distinct isoforms (type I and
type II) which are encoded by separate genes, have specific subcellular
localization and tissue distribution. Arginase I is a cytosolic enzyme
located primarily in the liver, whereas arginase II is located within
the mitochondrion and is expressed at high levels in the kidneys.1
However, both arginase isoforms are also expressed by endothelial
and vascular smooth muscle cells (VSMC).2 –4 Because nitric oxide
synthase (NOS) and arginase use L-arginine as a common substrate,
arginase may downregulate nitric oxide (NO) biosynthesis by com-
peting with NOS for L-arginine degradation. Consistent with this
hypothesis, NO production has been inversely correlated to arginase
activity in vessels at both physiological4 and pathological conditions
such as hypertension,5 atherosclerosis,6 diabetes,7 erectile dysfunc-
tion,8 and aging.9
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Endothelial dysfunction and associated impairment in vascular NO
production have been largely involved in the pathogenesis of arterial
hypertension.10 Surprisingly, the role of arginase in hypertension is
poorly documented. Increased arginase activity/expression was
reported in various vascular beds in models of essential or secondary
hypertension.11 –14 In addition, upregulation of arginase activity con-
tributes to attenuation of cutaneous vasodilation in hypertensive
humans.15 Recent studies from our laboratory reported that arginase
inhibitor prevented the development of hypertension and improved
aortic endothelial function via a NO-dependent mechanism when
administered to prehypertensive or young adult spontaneously hyper-
tensive rats (SHR).5,16 From these experimental and clinical data have
emerged the concept that arginase inhibition may represent a novel
strategy in hypertension. However, the potential antihypertensive
effect of arginase inhibition in SHR with fully developed hypertension
remains to be investigated. The efficacy of an antihypertensive treat-
ment should not to be solely estimated by the extent of blood
pressure (BP) reduction. Above and beyond BP values, it is necessary
to monitor the impact of the antihypertensive treatment on
hypertension-induced organ damage including vascular and cardiac
remodelling as well as arterial compliance.17 Again, so far the effect
of arginase inhibitor on these parameters is unknown.
The present study investigates the potential cardiovascular thera-
peutic effects of arginase inhibitor in adult SHR with fully developed
hypertension. For this purpose, Nv-hydroxy-nor-L-arginine (nor-
NOHA), a selective arginase inhibitor, was daily administered to
SHR at 25 weeks age for 10 weeks. The impact of treatment was
studied on systolic BP, reactivity of resistance vessels to vasodilating
and vasoconstrictive drugs, vascular and cardiac remodelling and
artery compliance. Wistar Kyoto rats (WKY) rats were evaluated in
parallel in order to investigate to what extent nor-NOHA-treated
SHR can recover in relation to control values.
2. Methods
2.1 Animals and treatment
Twenty-three male WKY rats and 42 SHR were purchased from Charles
River (L’Arbresle, France). Animals were kept under a 12–12 h light:dark
cycle and allowed free access to food and water. The investigation was
approved by the local Ethical Committee and conforms to the Guide
for the Care and Use of Laboratory Animal published by the US National
Institutes of Health (NIH publication No. 85–23, revised 1996).
At 25 weeks at age, SHR were randomly divided into two groups: SHR
(n ¼ 21) and nor-NOHA-treated SHR (n ¼ 21). Nor-NOHA (Bachem,
France) was dissolved in 0.9% NaCl and administered once a day
(40 mg/kg, ip) for 10 weeks. Control SHR received an equal volume of
saline daily. A group of untreated age-matched WKY rats was used as con-
trols (n ¼ 23). Systolic blood pressure (SBP) was measured once a week
in conscious rats by using the indirect tail-cuff method (BP2000, Visitech
System, Apex, NC, USA). At the end of the treatment period, rats were
anaesthetized (sodium pentobarbital, 60 mg/kg, ip) in order to collect
blood and various organs. Arginase activity was determined in liver and
kidney from the measurement of urea production according to the
method of Corraliza et al.,18 as previously described.5 Glucose levels
were measured in total blood using a blood glucose meter (Glucomen
Glyco´, A. Menarini diagnostics, Antony, France).
2.2 Vascular function
A third order branch of the mesenteric artery was isolated and mounted
on a pressurized myograph as described previously.16 After precontraction
with 1025 M phenylephrine (PE), endothelium-dependent and
-independent relaxation was assessed with acetylcholine (ACh, 10210 to
1024 M) and sodium nitroprusside (SNP, 10210 to 1024 M). To study the
role of NO, eicosanoids, and endothelium-derived hyperpolarizing factor
(EDHF) in ACh-dependent relaxation, vessels were pretreated (20 min)
with the NOS inhibitor Nv-nitro-L-arginine methyl ester (L-NAME,
1024 M), the cyclooxygenase (COX) inhibitor indomethacin (1025 M),
the Ca2+-dependent K+ channel inhibitors apamin (1027 M) and charybdo-
toxin (1027 M), respectively. Moreover, the response to PE (10210 to
1024 M), angiotensin-II (ANG-II, 10210 to 1024 M), and endothelin-1
(ET-1, 10210 to 1024 M) was investigated on mesenteric arteries with
intact endothelium as well as in preparations in which endothelium was
removed by perfusion with the detergent 3-[(3-cholamidopropyl)
dimethylammonio]-1-propane sulfonate (0.5%, 45 s). Complete endothelial
removal was verified by the absence in vasorelaxation capacity in response
to ACh in PE-preconstricted vessels.
2.3 Vascular compliance
The compliance was determined from the biomechanical analysis of the left
carotid (LCC) artery as previously described in detail.19,20 The LCC artery
was exposed in rats and mounted in our extension-inflation device
described elsewhere.19,20 The LCC artery was stretched to the individual
in vivo length for each rat. The artery was maintained in Krebs–Ringer sol-
ution at 378C and at a pH of 7.4 (continuously bubbled with standard gas:
O2–CO2 95–5%). The segment was then inflated with the constant rate of
5 mmHg/s. External diameter and intraluminal pressure were measured.
Arteries were preconditioned by means of inflation–deflation loops
(pressure range: 0–230 mmHg for WKY and 0–270 mmHg for SHR and
nor-NOHA samples) until the pressure–diameter (P–D) curve became
reproducible. The ascending limb of the last stable loop was used for
data analysis under normal conditions (normal VSMC tone). Then, KCl
was added to the bath to reach the final concentration of 100 mM, while
the artery was maintained at 100 mmHg. After 10 min, pressure was
lowered to 0 mmHg and raised to 230 mmHg for WKY arteries and 270
for SHR and nor-NOHA group, yielding the P–D curve under maximal
contraction (active VSMC state). Having the P–D sets of data and measur-
ing the zero load state geometry of the artery (inner and outer diameter),
the area compliance is determined as the slope of the cross-sectional area
(CSA)–pressure curve, C(P) ¼ dA/dP, where A is the lumen CSA and P the
interluminal pressure as previously described.19,20
2.4 Vascular remodelling
Remodelling of mesenteric arteries was assessed from the Media/Lumen
ratio (M/L) and media CSA as described previously.16 CSA was calculated
from the internal (Di) and external (De) diameters when the artery was at
75 mmHg pressure according to the formula: CSA ¼ p (De22Di2)/4.
Remodelling of aorta was assessed from the following parameters:
(i) the M/L ratio measured in paraffin-embedded tissue sections of aorta
after Masson’s trichromic staining, (ii) the collagen type I content
measured in Masson’s trichromic-stained sections and the elastin
content measured after orcein staining, (iii) the extracellular matrix metal-
loproteinases (MMPs) activity measured in aortic homogenates by using
the gelatin zymography method, as described below.
2.5 Expression of vascular enzymes
Frozen 8 mm sections of the mesenteric arteries were used for the detec-
tion of arginases and COX. Slides were incubated with and without (nega-
tive control) a primary antibody against rabbit anti-arginase I, rabbit
anti-arginase II, rabbit anti-COX-1, and rabbit anti-COX-2 and then
exposed to a fluorescent secondary antibody (IgG Alexa red conjugated
antibody, BD Biosciences). Finally, sections were mounted with DAPI-
containing mounting medium (Vectashield) and slides were analysed by
using a confocal microscope (Leica). The arterial expression of the
enzymes was quantified based on the intensity of the fluorescent staining
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subtracted by background intensity of negative control. Mean fluor-
escence intensity was obtained by dividing fluorescent intensity by the
area of the artery and reported as arbitrary units. Details of the
method are available in Supplementary Material.
2.6 Cardiac remodelling
Cardiac remodelling was assessed from different parameters including the
heart/body weight ratio (as an index of hypertrophy), the collagen I and III
content of the left ventricle (LV) after picrosirius red staining of
paraffin-embedded tissue, and MMPs activity of LV homogenates using
the gelatin zymography method, as described below.
2.7 Histological evaluation of the heart
and aorta
Tissues were fixed in Bouin’s solution and embedded in paraplast.
Transversally cut sections (5 mm) were stained with Masson’s trichromic
method for determination of the collagen type I content, and with
picrosirius red (0.1% solution in saturated aqueous picric acid) for deter-
mination of the collagen type I and III content. In addition, cross-section of
aortic artery was stained with orcein to determine elastin content.
Collagen or elastin content was measured with a semi-automated image
analysis software (AnalySIS 3.1, Soft Imaging System). The density of
collagen or elastin was averaged in 16 fields per section at a magnification
of ×200 and expressed as percentage of the total area within a field.
2.8 Gelatin zymography
Gelatinolytic activity of aortic and cardiac tissue homogenates was ana-
lysed by electrophoresis in the presence of 8% SDS–polyacrylamide
gels containing 1 mg/mL gelatin. Samples were applied to the gel in a
sample buffer containing 2.5% SDS but lacking b-mercaptoethanol.
A zymography standard (Chemicon International, Temecula, CA, USA)
containing pro- and active forms of MMP-2 and MMP-9 was used as posi-
tive control. After electrophoresis, gels were incubated at 378C in buffer
(100 mM Tris–HCl, pH 7.4, 100 mM NaCl, 5 mM CaCl2, 5 mM ZnCl2, and
0.02% BRIJ-35). Subsequently, gels were stained with Coomassie brilliant
blue G-250 for 1 h and then destained appropriately with a solution of
acetic acid/ethanol/water (1/2/7). MMP activity was quantified by measur-
ing optical density with an image analyser (Gel Doc XR, Bio-Rad, Her-
cules, USA) and expressed as the ratio of density of the sample related
to the density of the MMP control.
2.9 Statistical analysis
Values are given as means+ SEM. The pD2 values (calculated as the nega-
tive logarithm of the molar concentration that produced 50% of the
maximal effect) and Max values (values of maximal relaxation, Emax)
were determined by fitting the original dose–response curves using
Sigma Plot Software and compared by one-way analysis of variance
(ANOVA) followed by Bonferroni’s test. Dose–response relationships
were analysed using two-way ANOVA followed by Bonferroni’s test.
P, 0.05 was considered statistically significant.
Figure 1 Effect of nor-NOHA treatment on systolic blood
pressure (SBP). Twenty-five-week-old SHR were treated with
nor-NOHA (40 mg/kg/day, ip) or with vehicle for 10 weeks. SBP
was measured by the tail-cuff method before and once a week
after the beginning of the treatment. Values are means+ SEM
from 21 to 23 rats per group. #P, 0.05 vs. WKY rats, *P, 0.05
vs. untreated SHR.
Figure 2 Arginases and COX expression in mesenteric arteries.
(A) Representative figures (×40) for arginase I (a–c), arginase II
(d–f ), COX-1 (g–i), and COX-2 (h–j) expression in mesenteric
arteries from WKY rats, SHR, and nor-NOHA-treated SHR. (B–E)
Histograms for quantification of arginase I (B), arginase II (C ),
COX-1 (D), and COX-2 (E) in the different experimental groups.
Results are expressed as means+ SEM from 4 to 8 vessels.
#P, 0.05 vs. WKY rats, *P, 0.05 vs. untreated SHR.
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3. Results
3.1 Effects of nor-NOHA on physiological
parameters and arginase activity
As shown in Figure 1, nor-NOHA significantly decreased SBP in SHR.
The antihypertensive effect began from 2 weeks of treatment and
reached –30 mmHg after 5 weeks of treatment when compared
with untreated SHR (P, 0.05). The prolongation of the treatment
did not induce further changes in SBP. In addition, untreated SHR
and treated SHR exhibited similar blood glucose levels (1.01+ 0.05
vs. 1.03+ 0.05 g/L, respectively), heart rates (434+4 vs. 435+
6 bpm, respectively), and body weights (381+5 vs. 374+4 g,
respectively) (data not shown). Finally, nor-NOHA administration
did inhibit both arginase isoforms as evidenced by lower arginase
activity in liver (arginase I, 241%, P, 0.001) and kidney (arginase II,
240%, P, 0.001) in treated SHR than in untreated SHR (data not
shown).
3.2 Effects of nor-NOHA on arginase
and Cox vascular expression
Results are summarized in Figure 2. Genetic hypertension was associ-
ated with a two-fold increase in the expression of arginase I in mesen-
teric arteries (P, 0.05, Figure 2B), whereas arginase II expression was
unchanged (Figure 2C). Likewise, SHR exhibited a two-fold increase in
expression of COX-2 (P, 0.05, Figure 2E) but not of COX-1
(Figure 2D), as previously described.21,22 Hypertension-induced upregu-
lation of these enzymes occurred in endothelium for arginase I
(Figure 2A and B) and in both endothelium and VSMC for
COX-2 (Figure 2J and K). Nor-NOHA decreased the expression of
arginase I (Figure 2B and C) and COX-2 (Figure 2E and L) by 38%
(P, 0.05) and 27% (P, 0.05), respectively.
3.3 Effects of nor-NOHA on vascular
function
The results showed that nor-NOHA fully restored the response of
mesenteric arteries to ACh (Figure 3A) and ANG-II (Figure 3B) to
that of WKY rats, whereas it failed to ameliorate the response to
PE (Figure 3C) or ET-1 (Figure 3D). The removal of the endothelium
did not modify dose–response curves to any vasoconstrictive drugs
(data not shown). Additionally, no difference in SNP-induced vasodi-
lation was observed among WKY rats, treated SHR, and untreated
SHR (data not shown). In order to dissect the mechanisms involved
in the effect of nor-NOHA on ACh-induced vasodilation, the
dose–response curve of ACh was studied in the presence of
L-NAME, indomethacin, or apamin + charybdotoxin (Figure 4).
Figure 3 Effect of nor-NOHA on vascular reactivity. Experiments were conducted on the third order branch of the mesenteric artery isolated from
WKY rats, SHR, and treated SHR. (A) Cumulative concentration curves with acetylcholine (ACh). (B–D) Cumulative concentration curves with
(B) angiotensin-II (ANG-II), (C) endothelin-I (ET-1), and (D) phenylephrine (PE). The results are expressed as a percentage of the maximal constrictive
response to KCl 100 mM. Results are expressed as means+ SEM from eight vessels. *P, 0.05.
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Moreover, we calculated the Emax of ACh with or without the
inhibitor and the inhibitory effect of each inhibitor was expressed as
the percentage of reduction of Emax of ACh alone, as shown in
Table 1. Such kind of analysis allowed us to statistically compare
WKY rats, SHR, and nor-NOHA-SHR with respect to the contri-
bution of NO, COX products, and EDHF in ACh-induced vasodila-
tion. As shown in Figure 4, L-NAME, indomethacin and Apamin +
charybdotoxin significantly decreased the effect of ACh in all
groups. However, the data demonstrate that nor-NOHA significantly
improved the NOS- and COX-dependent components of ACh vaso-
dilation in SHR. Indeed, as shown in Table 1, the inhibitory effects of
L-NAME and indomethacin on ACh-induced maximal vasodilation
were greater in treated SHR when compared with untreated SHR
and were not different from that of WKY rats. In contrast, the contri-
bution of EDHF in the effect of ACh was not modified by nor-NOHA
(Figure 4C and Table 1).
Figure 4 Effect of L-NAME, indomethacin, apamin, and charybdotoxin on the mesenteric artery response to ACh. Experiments were conducted on
the third order branch of the mesenteric artery isolated from WKY rats, SHR and treated SHR. The cumulative concentration curves of ACh were
performed in the presence or not of (A) L-NAME 1024 M, (B) indomethacin 1025 M, (C ) Apamin 1027 M, and charybdotoxin 1027 M. Results are
expressed as means+ SEM from eight vessels. *P, 0.05.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Inhibitory effect of L-NAME, indomethacin,
apamin plus charybdotoxin on the maximal ACh-induced
vasodilation in mesenteric arteries
WKY (%) SHR (%) SHR nor-
NOHA (%)
L-NAME 1024 M 228+5 213+2# 229+2*
Indomethacin 10 25 M 230+4 27+3# 227+3*
Apamin (1027 M) +
charybdotoxin (1027 M)
230+5 280+2# 272+3#
The effects of drugs are expressed as the percentage of inhibition of the maximal
response to ACh 1024 M. Values are means+ SEM from eight vessels.
#P, 0.05 vs. WKY.
*P, 0.05 vs. SHR.
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3.4 Effects of nor-NOHA on vascular
and cardiac remodelling
The effects of arginase inhibition on hypertension-induced remodelling
of vessels and heart are shown in Table 2. Nor-NOHA prevented remo-
delling of aorta but not mesenteric arteries. Indeed, aorta media thick-
ness, M/L ratio, and collagen type I content were significantly lower in
treated SHR than in untreated SHR (232, 225, 217%, respectively,
P, 0.05, Table 2, see Supplementary material online, Figure S1).
However, nor-NOHA did not modify hypertension-induced increase
in pro- and native MMP-2 and MMP-9 activities (Figure 5), indicating
that the decrease in collagen content afforded by arginase inhibition
does not involve collagen degradation. Nor-NOHA did not significantly
reduce hypertension-induced cardiac hypertrophy (Table 2). However, it
reduced (253%, P, 0.05, Table 2, see Supplementary material online,
Figure S1) the collagen type I and III deposition by a mechanism indepen-
dent on MMPs activity as pro-MMP-2 and active MMP-2 were not differ-
ent between WKY rats, SHR, and nor-NOHA-treated SHR (see
Supplementary material online, Figure S2).
3.5 Effects of nor-NOHA on vascular
compliance
LCC artery compliance of each group have been calculated under
normal, maximally active (KCl) and passive tone (SNP) and at their
corresponding mean physiological pressures (135 mmHg for WKY
rats, 235 mmHg for untreated SHR and 200 mmHg for treated
SHR). As shown in Figure 6A, hypertension-associated decrease in
arterial compliance was significantly improved by nor-NOHA during
normal (P, 0.01), active (P, 0.001), and passive tone (P, 0.001).
Furthermore, at the pressure of 200 mmHg (i.e. the physiological
pressure for the treated SHR), nor-NOHA still improved arterial
compliance in KCl-contracted arteries (P, 0.005) and SNP-treated
arteries (P, 0.05) when compared with untreated SHR (Figure 6B).
These data indicate that the effects of nor-NOHA on arterial compli-
ance were not only due to pressure reduction but rather reflected
intrinsic changes in the vascular tissue.
4. Discussion
Increased vascular arginase expression has been previously reported
in animal models of hypertension. Secondary hypertension is associ-
ated with the upregulation of both arginase isoforms in gracilis
muscle arterioles from Dahl-salt sensitive rats,12 whereas only the
isoform I is overexpressed in coronary arterioles from pigs with
aortic coarctation.13 In genetic hypertension, we recently reported
an increase in the expression of both arginase isoforms in aorta of
SHR from the age of 5–26 weeks.14 The present study reports a
selective upregulation of the isoform I in mesenteric arteries of
35-week-old SHR, suggesting that the misregulation of the arginase
pathway is vessel and/or age-dependent in genetic hypertension.
Moreover, our results revealed that the decrease in arginase I
expression in nor-NOHA-treated SHR is associated to a decrease
in SBP. This result reinforces our previous findings that hypertension,
on its own, contributes to upregulate vascular arginase.14 Importantly,
the long-lasting and steady antihypertensive effects of the long-term
treatment with nor-NOHA reported here is consistent with the
idea that prolonged arginase inhibition does not induce a compensa-
tory upregulation of the enzyme.
Both endothelial dysfunction and abnormalities in VSMC reactivity
are known to contribute to increased vascular resistances in essen-
tial hypertension.23– 26 The present study provides arguments that
arginase inhibition controls vascular tone of resistance vessels not
only through increased NO production at the endothelial level as
previously described27 but also through a decreased VSMC reactivity
to ANG-II. Moreover, our results indicate that besides increased
NO production, COX-dependent mechanisms are involved in the
improvement of ACh-induced vasodilation by nor-NOHA. Evidence
of decreased vascular COX-2 expression by nor-NOHA strongly
suggests that the production of vasoconstrictor eicosanoids by
COX-2 is reduced after arginase inhibition. However, increased
production of vasodilating eicosanoids cannot be excluded since
endothelial COX activity is stimulated by NO.28 Further studies
are needed to elucidate the intimate mechanisms involved in the
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Table 2 Effects of nor-NOHA on vascular and cardiac remodelling
WKY SHR SHR nor-NOHA
Mesenteric artery
Media thickness (mm) 18.8+0.5 26.8+0.9* 26.2+0.9*
Lumen (mm) 282.7+5.6 282.7+4.8 255.8+8.7
M/L ratio (%) 6.7+0.2 9.5+0.3* 10.4+0.4*
Media cross-sectional area (mm2) 8638.1+321.5 12492.1+518.1* 11203.0+625.3*
Aorta
Media thickness (mm) 53.1+1.4 97.6+0.9* 66.2+2.3*#
Lumen (mm) 1675.1+26.9 1778.0+29.7 1601.1+44.6
M/L ratio (%) 3.2+0.1 5.5+0.3* 4.1+0.3*#
Collagen type I (% of area) 22.1+2.4 36.9+3.8* 30.7+3.0*#
Elastin (% of area) 20.8+1.9 23.7+2.4 23.3+0.9
Heart
Heart/body weight ratio (%) 23.2+0.3 36.8+0.6* 38.3+0.5*
Left ventricle intersticial collagen type I and III (% of area) 4.4+0.4 11.3+1.5* 5.3+0.4*#
Values are means+ SEM (n ¼ 8).
*P, 0.05 different from WKY rats.
#P, 0.05 different from untreated SHR.
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Figure 5 Effect of nor-NOHA on MMP activity in aortas. MMP-2 and MMP-9 activities were determined by gelatin zymography of aortic tissue from
WKY rats, SHR and treated SHR. The upper panel shows a representative zymogram of samples and of the MMP control (last right lane), and the
lower panels illustrate the densitometric analysis of lytic bands (expressed as the ratio of density of the sample related to the density of the MMP
control) of MMP-2 (A), pro-MMP-2 (B), MMP-9 (C ), and pro-MMP-9 (D). Values are means+ SEM (n ¼ 8). *P, 0.05 vs. WKY rats.
Figure 6 Effect of nor-NOHA on carotid artery compliance. Arterial compliance was determined in carotid arteries from WKY rats, SHR and
treated SHR, as described in Methods. The measurements were made (A) under corresponding physiological pressure for each group and (B) at
the nor-NOHA-treated group pressure (200 mmHg), under normal resting (normal), totally contracted (KCl), and totally dilated (SNP) state of vas-
cular smooth muscle cells. Values are means+ SEM from 6–8 vessels. *P, 0.05 vs. WKY rats, #P, 0.05 vs. untreated SHR.
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crosstalk between arginase, ANG-II, and COX pathways in
hypertension.
Vascular remodelling of conduit and resistance vessels is well ident-
ified as a contributing factor to the hypertensive process.29 In fact,
structural alterations at arterial wall are not only a normal adaptation
to raised BP, but also participate to the persistence of the increased
BP. Our data provide the first evidence that arginase inhibition can
prevent aortic remodelling observed in essential hypertension. Consid-
ering that vascular remodelling is an adaptative response to the BP
elevation,30 the antihypertrophic effect of nor-NOHA may be related
to the long-lasting decrease in BP afforded by the treatment.
However, based on previous studies using different antihypertensive
drugs, the reduction in BP by itself appears to be not sufficient to
reduce cardiovascular remodelling.31 Besides the synthesis of urea, argi-
nase is also involved in the production of ornithine, the precursor of
polyamines and proline.1 Thus, nor-NOHA might exert antihyper-
trophic effects through a decrease in the synthesis of polyamines, com-
pounds largely involved in cell growth/proliferation.32,33 Indeed, results
from in vitro experiments showed that polyamine synthesis is increased
after stable transfection of arginase cDNA in cultured endothelial
cells.34 Likewise, the reduction of collagen deposition in aorta afforded
by nor-NOHA might derive from a decrease in the availability of
proline, the precursor of collagen synthesis. In agreement, decreased
collagen synthesis rather than increased collagen catabolism is likely
involved in the reduction of collagen deposition as evidenced by the
lack of effect of arginase inhibition on aortic MMPs activity. However,
the benefit of arginase inhibition on aortic remodelling may be in
part mediated by a reduction of the VSMCs growth since arginase is
essential for cultured rat aortic VSMC to enter in the cell cycle.35 Of
note, nor-NOHA prevented remodelling of aorta but not of mesen-
teric arteries, suggesting that the mechanisms underlying vascular remo-
delling might be vessel dependent.36 Importantly, the lack of impact of
nor-NOHA on remodelling of small vessels does not question its
potential lowering effect on diastolic BP which is determined by periph-
eral vascular resistance. Indeed, vascular resistance depends on vascular
structure but also on vascular tone29,37 which is improved after arginase
inhibition. Finally, our results also report decreased collagen deposition
in heart without accompanying changes in MMPs activity after
nor-NOHA treatment. This data may open new perspectives on the
regulation of cardiac collagen synthesis by arginases after hypertension.
Clinical studies demonstrated that hypertension is associated with
stiffening of conduit arteries leading to decreased arterial compliance,
which is now recognized as an important and independent cardiovas-
cular risk factor.38 Conduit vessel stiffness is, in part, regulated by the
smooth muscle tone (which is influenced by circulating and
endothelium-derived vasoactive mediators including NO and
ANG-II) and extracellular matrix.39 In agreement with previous
studies,40,41 the present results showed that arterial compliance is
reduced in untreated SHR when compared with WKY rats. The
new finding of our study is that nor-NOHA treatment dramatically
increases the arterial compliance of SHR. Of note, a recent study
showed that the arginase inhibitor S-(2-boronoethyl)-l-cysteine
restored arterial compliance in atherosclerotic apolipoprotein-E
deficient mice.6 Taken together, these data suggest that arginase is a
new potential target to reduce arterial stiffness.
In conclusion, our results demonstrate that arginase inhibition in
SHR with fully developed hypertension reduced systolic BP and
target organ damage including artery remodelling, cardiac fibrosis,
and changes in vascular compliance. These results suggest that
arginase is a promising target to reduce BP and to improve cardiovas-
cular function in patients with essential hypertension. Arginase inhi-
bition might also be useful for reducing cardiovascular risk in
hypertensive patient since a large meta-analysis of trials in hyperten-
sion reported that antihypertensive drug treatment improves cardio-
vascular outcome mainly through lowering of SBP.6 Interestingly,
recent clinical studies confirmed the critical role of arginase in the
control of BP. More precisely, plasma arginase activity is high in
hypertensive pre-eclamptic women and correlates with plasma NO
and BP levels.42 Additionally, BP level, risk of myocardial infarction
and common intima-media thickness are dependent on arginase I
polymorphisms.43,44
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